Vitamin B3 Reversed Body-Wide Damage from NAD Loss in Mice; Why Niacinamide Is the Preferred Form

Niacinamide

Story at-a-glance

NAD is a coenzyme every cell needs to turn food into energy, repair DNA, and run its repair and renewal programs.

A new Mayo Clinic study starved young mice of NAD for months. The result was frailty, bone and muscle loss, cataracts and an early death. Six weeks of ordinary vitamin B3 reversed most of it.

The researchers rescued the mice with nicotinic acid, the form in standard lab diets. That doesn’t make it the best form for you, though. The way your body actually builds NAD points to niacinamide.

Taken by mouth, the expensive precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are largely converted to plain niacinamide in your liver. A 2026 phase 3 trial of NR in Parkinson’s patients found they did worse than on placebo.

Niacinamide is the fuel. The enzyme NAMPT is the bottleneck that turns it into NAD, and exercise and fasting turn NAMPT up.

https://articles.mercola.com/sites/articles/archive/2026/11/16/niacinamide-nad-levels.aspx

Quote of the Day

‘Success is not final, failure is not fatal: it is the courage to continue that counts.’
Winston Churchill – Statesman (1874 – 1965)

How Ida Tarbell Took Down Rockefeller

Ida Tarbell

John D. Rockefeller was the most powerful businessman in America. When a magazine series took apart his company, piece by piece, over nineteen installments, his public answer was silence.

The woman who wrote it had been waiting most of her life.

Ida Tarbell grew up in the Pennsylvania oil fields, where her father, Franklin Tarbell, was an independent oil producer. In the early 1870s, a scheme tied to the railroads threatened to squeeze small producers like him out of business. Rebates went to the favored few. Everyone else paid more to ship the same barrel.

She was a teenager. She watched her father and his neighbors come to believe the game was rigged. She never forgot it.

Decades later, she was a working journalist, and S.S. McClure’s magazine gave her a job that looked impossible: explain how Standard Oil really became Standard Oil.

She did not go in swinging. She went in with paper.

She dug through court records, legislative testimony, and old company documents. She interviewed men who had been inside the oil trade and men who had been crushed by it. According to most accounts, she also sat down privately with Standard Oil executive Henry H. Rogers, who answered some of her questions.

Then she did the slow thing. She checked the dates, matched the figures, and wrote it so plainly that nobody could say she had guessed.

The series ran in McClure’s from November 1902 to May 1904. Nineteen parts. Cleveland, Pittsburgh, the oil regions, the courtrooms in Washington. A single company’s rise, laid out like a ledger.

Rockefeller’s reply was to say nothing in public.

The case against Standard Oil kept moving anyway. In 1911, the U.S. Supreme Court ruled that the company had to be broken up. It was split into 34 separate companies.

Some of their descendants are still on the sign above the gas station today: ExxonMobil, Chevron, ConocoPhillips, Marathon.

She did not win with rage. She won with receipts.

The daughter of an oil producer who was squeezed out.

The reporter who read every page.

The nineteen chapters that a monopoly could not answer.

Timnit Gebru

Timnit Gebru

(Tom: What was Google’s motto… …”Do no evil.” wasn’t it? Seems they have fallen a long way from that.)

GOOGLE HIRED HER TO MAKE AI MORE FAIR. WHEN SHE RAISED DIFFICULT QUESTIONS, HER DEPARTURE BECAME A GLOBAL CONTROVERSY.

Timnit Gebru was born in Ethiopia and spent her early years in Addis Ababa.

As a teenager, she and her family experienced the upheaval surrounding the Eritrean-Ethiopian conflict. She eventually made her way to the United States, where she began rebuilding her life as a refugee.

Starting high school in a new country was not easy. Despite being a strong student, she faced resistance when trying to enter advanced classes. She persisted.

That determination would take her to Stanford University, where she earned a PhD in electrical engineering.

But Gebru would become known for something much bigger than her academic achievements.

In 2018, she co-authored a landmark study called Gender Shades, which examined racial and gender disparities in commercial facial-analysis systems.

The findings exposed a serious problem: some systems performed far worse on darker-skinned women than on lighter-skinned men.

The research helped bring worldwide attention to bias in facial recognition technology and the consequences of building systems that do not work equally well for everyone.

That same year, Google hired Gebru as a co-lead of its Ethical AI team.

She helped build a research group focused on examining the social consequences of artificial intelligence, including discrimination, fairness, and accountability.

Then came the paper that would put her at the centre of one of the technology industry’s most widely discussed controversies.

In 2020, Gebru co-authored a research paper titled “On the Dangers of Stochastic Parrots: Can Language Models Be Too Big?”

It raised difficult questions about the growing use of massive language models.

The researchers highlighted three major concerns:

1. BIAS

AI systems learn from enormous collections of human-created information. When that information contains racism, sexism, and other forms of discrimination, models can reproduce and sometimes amplify those patterns.

2. ENVIRONMENTAL COST

Training increasingly large AI models can consume substantial energy and generate significant carbon emissions. The paper questioned whether the benefits justified the environmental costs.

3. ACCOUNTABILITY

When datasets become enormous and difficult to examine, identifying harmful patterns, documenting their origins, and understanding their effects becomes much harder.

The paper did not argue that AI research should simply stop. It called for greater scrutiny, transparency, and accountability as these systems grew.

Google’s research leadership objected to the paper, arguing that it did not meet the company’s standards for publication.

Gebru challenged the process and asked for greater transparency about the review and the reasons for the objections.

She also raised concerns about the company’s treatment of researchers working on bias and the representation of underrepresented groups.

In December 2020, Gebru announced that her employment at Google had ended.

Google described the situation as her resignation. Gebru said she had been forced out.

The disagreement sparked an international debate about research independence, workplace treatment, and whether technology companies were willing to publish criticism of their own products.

Thousands of Google employees and researchers signed a protest letter. Members of the US Congress also sought answers from the company.

But Gebru did not walk away from the work.

On December 2, 2021, she launched the Distributed AI Research Institute (DAIR), an independent research organisation focused on examining how artificial intelligence affects society, particularly communities that are often overlooked in technology development.

Its mission was to conduct research outside the control of major technology companies, giving researchers greater independence to investigate the effects of AI.

Her work continued to receive international recognition.

In 2021, Nature included her among its influential scientists of the year.

In 2022, TIME named her one of the 100 Most Influential People.

In 2023, the BBC included her in its 100 Women list.

Think about the journey.

A young girl who experienced conflict and displacement. A refugee who rebuilt her education in a new country. A researcher who helped expose inequalities in facial recognition. A scientist who questioned the environmental and social costs of increasingly powerful AI systems.

And when a major technology company became the centre of a public dispute over her research, she went on to help build an independent institution.

The questions she raised remain important:

Who benefits from artificial intelligence?

Who is overlooked when these systems are designed?

Who is responsible when they cause harm?

And who gets to decide which concerns deserve to be heard?

Timnit Gebru’s story is not simply about one scientist and one company.

It is also about the importance of independent research, transparency, and accountability in a technology that is rapidly becoming part of everyday life.

The Forgotten Causes of Alzheimer’s and the Cures They’ve Buried

Change In Cognitive Performance

After decades and billions spent chasing amyloid, a new body of evidence is revealing the real causes of dementia and decades of forgotten research for healing cognitive decline is being rediscovered.

Story at a Glance:

•Alzheimer’s disease is commonly thought to result from abnormal plaque buildup in the brain that gradually destroys brain tissue. As a result, almost all Alzheimer’s research has been directed toward eliminating amyloid, even after the basis for much of this work was shown to stem from fraudulent research.

•As such, despite decades of research and billions of dollars spent, this model has completely failed to produce useful results. The costly “groundbreaking” Alzheimer’s drugs only slightly slow dementia progression—at the expense of causing brain bleeding and swelling in over a quarter of those treated. In April 2026, the most rigorous independent review of these drugs to date concluded they make no meaningful difference to patients.

•In contrast, numerous affordable treatments have been developed for Alzheimer’s disease that target the root causes of the disorder, producing significant benefits at a fraction of the cost and without any toxicity.

•One neurologist, for example, proposed that amyloid serves a protective function in the brain and treats Alzheimer’s by identifying the underlying process causing dementia (which can often be diagnosed through symptoms). Remarkably, despite the method being proven in clinical research (and now a randomized controlled trial), awareness of it or the fact there are completely different types of “Alzheimer’s disease” which require different treatments remains almost nonexistent.

•Likewise, a strong case can be made that impaired cerebral circulation, along with impaired venous and lymphatic drainage, plays a pivotal role in Alzheimer’s disease.

•A large body of forgotten research (much of it from Russia) shows that blood cells clumping together (“blood sludging”) obstructs the brain’s smallest vessels and can precede the brain changes seen in Alzheimer’s—a process Chinese medicine has long recognized as “blood stasis.”

•This article will review the common causes of cognitive impairment and dementia (e.g., cells becoming trapped in a shocked state where they no longer function) along with the forgotten treatments for neurodegenerative disorders—some of which, like DMSO, have extensive evidence supporting their use.

One of the least appreciated aspects of medicine is the numerous frameworks that have been developed to understand how the body works, why it gets sick, and how to heal it. This, I believe is a result of conventional medicine having successfully branded itself as the one true path to understanding the body and each remaining approach being a “second-rate gimmick,” which at best, can sometimes assume a complementary role in healthcare.

However, if you study those other approaches, you will find each medical system excels at certain types of health problems, while struggling with others, so in many instances, knowing which medical model to jump to can be immensely beneficial to patients.

The modern approach to medicine is heavily biased towards a biochemistry model, where customized drugs are designed to stimulate or inhibit specific molecular targets (most commonly enzymes, frequently cellular receptors or ion channels, and less often, other aspects of the body, such as individual genes or inflammatory messengers). This approach, in turn, tends to excel for specific issues (particularly acute emergencies) but typically struggles with chronic ailments—something I attribute both to target molecules rarely being able to reach broad swathes of the body and partly due to living organisms being designed to adapt to excessive stimulation or inhibition of specific receptors and enzymes within the body.

Yet despite its frequent failures, we continue to rigidly adhere to that model of medicine. This I believe, ultimately is because therapies produced within this framework are highly specific to individual diseases (hence allowing many distinct patentable products), and in many cases (since they can only temporarily shift an enzyme or receptor) do not produce lasting cures—hence requiring perpetual purchases of them and thus recurring pharmaceutical sales.

Note: in many cases, disabling critical enzymes or receptors also creates a myriad of side effects (particularly over time as the body readjusts itself to accommodate this unnatural state).

All of this summarizes why, despite spending an ever increasing amount of money on Alzheimer’s research (e.g., the NIH spent 2.9 billion in 2020 and 3.9 billion in 2024), we have still failed to make any real progress on the disease. Furthermore, we only spend that much money on Alzheimer’s research because of how dire its costs are (e.g., in 2024 it was estimated to cost the United States 360 billion dollars). Sadly, this figure only touches the surface of the social cost (as any relative of someone with Alzheimer’s can attest)—again making it so remarkable we still have not made any progress in the illness.

Finish reading: https://www.midwesterndoctor.com/p/the-forgotten-causes-of-alzheimers?r=yh8aw